October 23, 2012
Gonax for Subcutaneous Injection Launched on October 23 Astellas Pharma launched its GnRH (gonadotrophin-releasing hormone) antagonist Gonax for Subcutaneous Injection 80 mg/120 mg (degarelix acetate) for prostate cancer on October 23. The launch will mark the company’s full-fledged entry into...read more